Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Renalytix ( (GB:RENX) ) is now available.
Renalytix has completed the transfer of its laboratory operations to a new state-of-the-art facility in New York, boosting kidneyintelX.dkd testing capacity by more than 3.5 times to support over 100,000 tests annually while cutting fixed operating costs. The move is expected to deliver immediate gross margin improvement, material long-term cost savings exceeding $2.6 million over five years, and enhanced operating leverage as volumes scale.
The company has also finalized submission of the technical file for CE marking of kidneyintelX.dkd, a key step toward use in global pharma clinical trials and commercialization in select European markets. Renalytix anticipates completing the CE marking process in Q3 2026, initiating patient testing and data generation at Denmark’s Steno Diabetes Center in Q4 2026, and expanding to revenue-generating testing across multiple sites in 2027, strengthening its international growth prospects.
Spark’s Take on RENX Stock
According to Spark, TipRanks’ AI Analyst, RENX is a Underperform.
The score is constrained primarily by weak financial fundamentals (large losses, heavy cash burn, and negative equity). Technicals add further downside risk with a strong downtrend and negative momentum, while valuation is also pressured by ongoing losses and no dividend support.
To see Spark’s full report on RENX stock, click here.
More about Renalytix
Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. Its flagship product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in diabetic kidney disease and is commercially offered in the U.S., with deployment across large physician groups and health systems.
Average Trading Volume: 995,181
Technical Sentiment Signal: Sell
Current Market Cap: £8.52M
For a thorough assessment of RENX stock, go to TipRanks’ Stock Analysis page.